Marex Group’s Guardant Health GH Stock Holding History

Marex Group’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,492	Closed	-$323K	–	1226
2026 Q1	$323K	Buy	+3,492	New	+$351K	﹤0.01%	752

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Marex Group's GH Position: Q2 2026 in Review

Marex Group sold out of Guardant Health (GH) in Q2 2026, closing a stake of 3,492 shares — an estimated $323K sold.

Marex Group first reported a position in GH in Q1 2026 and held it in 1 quarter. The position peaked at $323K in Q1 2026. 597 funds tracked by Wall St. Rank hold GH as of Q2 2026.

Marex Group reported no remaining Guardant Health position as of Q2 2026 after selling out during the quarter.
Marex Group sold 3,492 Guardant Health shares in Q2 2026, an estimated $323K.
Marex Group first reported a position in Guardant Health in Q1 2026 and held it in 1 quarter.
Marex Group's Guardant Health position peaked at $323K in Q1 2026.
597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.